ASX: ALQ
2026 aug
ALS Ltd
...................................................
ALS Limited (ASX: ALQ) is a global testing, inspection, and certification (TIC) company headquartered in Brisbane, Australia. It trades at approximately AU$22.50 with a market cap near AU$11.4 billion, providing analytical laboratory services across the mining, environmental, and life sciences sectors globally. [1, 2, 3, 4]
Core Business Segments
- Life Sciences: Environmental testing (water, soil, air), food safety, and pharmaceutical analysis.
- Commodities: Assay and analytical testing for minerals and mining exploration companies.
Financial Highlights
- FY2026 Performance: Delivered record results with revenue up 10.7% to AU$3.32 billion and underlying net profit (NPAT) up 25.8% to AU$381.2 million. [1]
- Targets: Reached its strategic fiscal 2027 financial goals a year ahead of schedule due to robust organic growth in the commodities sector. [1, 2]
- Dividend Yield: Offers a trailing yield of roughly 1.8%. [1]
Growth Drivers
- Global Megatrends: Benefiting from tighter environmental regulations and increased contaminant monitoring.
- Energy Transition: High demand for mineral exploration and critical energy-transition metals drives ongoing laboratory utilization
............................
PE
Over the last decade, ALS Limited's P/E ratio has experienced dramatic fluctuations. This volatility was largely driven by commodity cycle impacts on its mining testing division, alongside unique non-cash accounting adjustments—culminating in a major outlier spike in 2024 when paper earnings compressed relative to share price: [1, 2, 3]
| Year | Year-End P/E Ratio | Key Market Drivers & Context |
|---|---|---|
| 2026 (Mid-Year) | 35.74 | Driven by standard revenue growth in life sciences & core professional testing. |
| 2025 | 32.3 | Normalized valuation following consecutive periods of recovering core net profit margins. |
| 2024 | 503.0 | Massive mathematical anomaly due to steep declines in statutory net profit after abnormals. |
| 2023 | 20.0 | A localized cyclical low as macro-economic tightening slowed market exploration volumes. |
| 2022 | 28.7 | Resilient post-pandemic baseline bolstered by secular expansion in environmental testing. |
| 2021 | 34.2 | Commodity boom rebound lifting geochemical volume demands across global mining sectors. |
| 2020 | 29.1 | Pandemic disruption managed effectively via strong balance sheet preservation. |
| 2019 | 21.0 | Industry consolidation period following historical segment shifts. |
| 2018 | 53.8 | Prior cycle peak valuation before accounting impairments adjusted down trailing expectations. |
| 2017 | 27.9 | Turnaround operational year following the mid-decade minerals market crash. |
| 2016 | -5.46 | Negative ratio owing to deep statutory losses amidst global commodities downturns. |
🔎 Contextual Insights for Investors
- The 2024 Accounting Anomaly: The astronomical 503x P/E ratio in 2024 is technically valid on a statutory basis but does not represent structural cash generation. While underlying adjusted operational cash flow remained strong, severe non-cash abnormal items pushed statutory net income close to zero, artificially ballooning the P/E formula (Price ÷ negligible EPS). [1, 2, 3]
- Premium Valuation to Peers: At roughly 35.7x, ALQ consistently trades at a high premium relative to the wider ASX Industrials sector average, which hovers closer to 12.2x. This reflects structural tailwinds in their globally dominant life sciences testing, testing verification systems, and environmental compliance wings. [1, 2]
......................
Over the past 10 years, ALS Limited (ASX:ALQ) has delivered strong, resilient financial performance, highlighted by record revenue of AU$3.32 billion and a net profit after tax of AU$318.7 million in FY26. The testing and inspection services provider maintained an unbroken 10-year streak of profitability with solid return on equity (ROE) near 20% and manageable debt leverage. [1, 2, 3]
Profit and Revenue
- Revenue growth: Scaled steadily from past cycles to a record AU$3.32 billion in FY26, backed by strong organic growth in the Commodities and Life Sciences divisions. [1]
Debt and Financial Health
- Debt levels: Carries a moderate long-term debt load (around AU$1.45 billion) against total shareholder equity of roughly AU$1.7 billion. [1, 2]
- Leverage: Maintains a healthy debt-to-equity ratio near 0.92, which is standard and safe for a highly cash-generative global testing business. [1]
Return on Equity (ROE) & Efficiency
- ROE performance: Delivered robust capital efficiency, maintaining an average Return on Equity (ROE) of roughly 20% to 23% over recent multi-year periods.
Dividends
- Growth: Increased dividends by an average of about 6.3% per year over the past 10 years.
...............
ROIC vs WACC
For ALS Limited (ASX:ALQ), the Return on Invested Capital (ROIC) generally exceeds its Weighted Average Cost of Capital (WACC). Current financial estimates place ALQ's ROIC at approximately 12.8% to 13%, while its WACC sits lower at roughly 8% to 9.7%. [1, 2, 3, 4]
Value Creation Analysis
.............................
EPS over the last 10 years
ALS Limited (ASX:ALQ), often tracked under the ticker ALS, reported a statutory earnings per share (EPS) of AU$0.63 for the full financial year 2026. Over recent fiscal years, the company's underlying and statutory performance has reflected strong recovery in its commodities and testing sectors. [1]
Recent Financial Year EPS Performance
- FY2026: AU$0.63 (Statutory) / AU$0.757 (Underlying)
- FY2025: AU$0.53 (Statutory)
- FY2024: AU$0.39 (Adjusted baseline low)
- FY2023: AU$0.61
Key Trends & Observations
- Growth Trajectory: EPS figures demonstrate a cyclical trend closely tied to global mineral exploration and testing demand within the Commodities and Life Sciences divisions. [1, 2]
- Data Access: For detailed year-by-year financial metrics, full statutory accounts, and historical reports spanning the complete 10-year period, visit the official ALS Global Financial Reports portal. [1]
.................
FCF
Free cash flow
Over the last ten fiscal years, ALS Limited (ASX: ALQ)—trading under ticker ALQ—has demonstrated generally strong and positive cash generation from its global testing, inspection, and certification operations. Free cash flow (calculated as operating cash flow minus capital expenditures) has fluctuated alongside commodity cycles and strategic capital investments. [1]
Ten-Year Free Cash Flow Trend
- FY2026: $674.1 million (record cash generation driven by strong organic growth and 92% EBITDA cash conversion)
- FY2025: ~[A$222.7 million to A$250 million range based on recent trailing metrics]
- FY2017–FY2024: Maintained largely positive annual free cash flows averaging between A$150 million and A$300 million per year, reflecting resilient non-discretionary testing demand in commodities and life sciences.
Cash Generation Highlights
- High Conversion: ALS consistently achieves high EBITDA-to-cash conversion rates, frequently tracking at or above 90%.
................
ARGO vs ALS - buffett style sept 2026
ALS Limited (ASX: ALQ) has delivered vastly superior long-term compound growth compared to Argo Investments (ASX: ARG) over the past decade, driven by aggressive global expansion, whereas Argo functions as a conservative, broad-market proxy.
From a strict Warren Buffett-style investment lens—prioritizing durable economic moats, predictable earnings growth, and consistent compounding—these two structures represent fundamentally different allocations of capital.
28 Sept 2026 10:00 am - 1:00 pm
Open9.17 | Mkt cap$6.83B AUD | 52-wk high9.57 |
High9.19 | P/E ratio26.48 | 52-wk low8.45 |
Low9.06 | Div yield- |
Financial Comparison Matrix (2026)
| Metric | Argo Investments (ASX: ARG) | ALS Limited (ASX: ALQ) |
|---|---|---|
| Business Structure | Listed Investment Company (LIC) | Global Testing, Inspection & Certification |
| Trailing P/E Ratio | 26.5x | 32.8x |
| Dividend Yield | ~4.3% (Forward) | ~2.0% (Trailing) |
| Franking Credits | 100% Fully Franked | ~30% Partially Franked |
| 10-Year Comp. Return (p.a.) | ~9.0% | ~14.7% (5-year pace baseline) |
| 10-Year Dividend Growth (p.a.) | ~2.7% | ~9.2% to 10.7% (Recent multi-year CAGR) |
Buffett-Style Breakdown
1. The Economic Moat (The Franchise)
2. Dividend & Capital Allocation Efficiency
- Argo (ARG): Functions as a traditional "income smoother". It pays out nearly all received dividend income to pass through 100% franking to retail investors. However, its dividend payout is frequently unhedged by direct organic earnings growth, requiring capital gains realization to sustain payouts. [1, 2, 3, 4]
3. Value & Margin of Safety
- Argo (ARG): Consistently trades near its Net Tangible Assets (NTA) backing. At a 26.5x P/E, it mirrors an elevated, mature Australian equities baseline valuation.
- ALS (ALQ): Typically commands a premium structural growth multiple (~32.8x P/E). While it exhibits higher volatility and capital leverage ($1.8B+ debt load), its consistent double-digit revenue expansion provides a dynamic runway for long-term equity growth
................................
More Buffett analysis
Return on Equity (ROE) Trend Analysis
An analysis of ALS Limited (ASX: ALQ) shows that the company consistently delivers high-tier financial efficiency, with a Trailing Twelve Month (TTM) Return on Equity (ROE) hovering between 21.4% and 22.9%. [1, 2]
This is significantly higher than the mid-teens average typical for the diversified industrials sector. [1]
However, looking at the historical trajectory from FY24 through FY26, a slight downward trend in ROE emerges alongside changes in its capital structure:
| Metric | FY2024 | FY2025 | FY2026 (Provisional/TTM) |
|---|---|---|---|
| Return on Equity (ROE) | 25.7% | 23.8% | 22.9% |
| Shareholders' Equity | $1,183.3M | $1,279.7M | $1,699.8M |
| Return on Invested Capital (ROIC) | 10.6% | 12.0% | 12.8% |
- The Dilution Effect: The compression in ROE is primarily driven by a rapidly expanding equity base (which grew from $1.18B to $1.70B). Net Profit After Tax (NPAT) expanded significantly over the period ($318.7M in FY26), but the scale of the capital base grew faster. [1]
- The ROIC vs. ROE Spread: Interestingly, while ROE softened slightly, ROIC actually improved from 10.6% to 12.8%. This points to strong operational performance from their underlying assets and standard standardized laboratory networks. The spread between ROE and ROIC is largely amplified by financial leverage. [1, 2]
Capital Allocation vs. Buffett Benchmarks
Warren Buffett’s capital allocation framework relies on three fundamental pillars: a sustainable economic moat, high returns on retained earnings, and disciplined debt management.
1. The Retained Earnings Test ("The $1 Rule")
- The Benchmark: Buffett dictates that a company should only retain earnings if every $1 retained creates at least $1 of market value.
- ALQ's Performance: ALQ maintains a payout ratio of 55% to 63%. The remaining ~40% of earnings are funneled into aggressive bolt-on acquisitions (primarily expanding their global Life Sciences network). With its market capitalization sustained above $10.5 billion and EPS growing dynamically, ALQ passes this test comfortably. Capital expenditure and acquisitions have successfully unlocked operating leverage. [1, 2, 3, 4]
2. The Moat & Pricing Power
- The Benchmark: Buffett prioritizes companies with a structural competitive advantage that can maintain high returns without losing market share to competition.
3. Debt and Financial Risk
- The Benchmark: Berkshire Hathaway avoids companies that generate high ROE purely by stacking high layers of risky debt.
- ALQ's Performance: A Flag for Caution. ALQ’s total debt profile has expanded significantly to fund its M&A strategy, pushing its debt-to-equity ratio up past 1.62 in recent cycles. While its Net Debt/EBITDA is managed at a manageable ~1.7x, the heavy reliance on leverage means its impressive >21% ROE is partially engineered via the balance sheet rather than pure organic equity efficiency. [1, 2, 3]
Strategic Summary
From a Buffett perspective, ALQ is a high-quality, moated franchise with phenomenal pricing power and an asset-light structure in key divisions. However, a purist value investor would flag its recent debt-fueled acquisition pace. The core metric to monitor moving forward is whether future earnings growth from these newly acquired global laboratories outpaces the rising cost of servicing that debt. [1, 2, 3]
................
................
